Serina Therapeutics (SER) Debt to Equity (2017 - 2025)

Historic Debt to Equity for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $1.64.

  • Serina Therapeutics' Debt to Equity rose 30341.09% to $1.64 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.64, marking a year-over-year increase of 30341.09%. This contributed to the annual value of -$1.05 for FY2022, which is 584.89% up from last year.
  • Serina Therapeutics' Debt to Equity amounted to $1.64 in Q3 2025, which was up 30341.09% from -$0.81 recorded in Q3 2024.
  • In the past 5 years, Serina Therapeutics' Debt to Equity registered a high of $1.64 during Q3 2025, and its lowest value of -$2.42 during Q1 2024.
  • Its 5-year average for Debt to Equity is -$0.93, with a median of -$1.05 in 2022.
  • Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 90500.79% in 2024, then surged by 30341.09% in 2025.
  • Over the past 5 years, Serina Therapeutics' Debt to Equity (Quarter) stood at -$1.11 in 2021, then grew by 5.85% to -$1.05 in 2022, then skyrocketed by 92.33% to -$0.08 in 2023, then crashed by 905.01% to -$0.81 in 2024, then skyrocketed by 303.41% to $1.64 in 2025.
  • Its last three reported values are $1.64 in Q3 2025, -$0.81 for Q3 2024, and -$0.68 during Q2 2024.